BVF Inc.

In its 13F for Q1 2025 (holdings as of March 31, 2025, filed May 15, 2025), BVF Inc. reported 51 stock positions worth $2.5 billion. Its top holding was Moonlake Immunotherapeutics (MLTX) at 31.5% of the portfolio, followed by Axsome Therapeutics (AXSM, 8.0%) and Revolution Medicines (RVMD, 7.2%). Compared with Q4 2024, it opened 2 new positions, sold out of 4, added to 12 and reduced 5. The biggest buy was Axsome Therapeutics (AXSM, shares +22%) and the biggest sale an exit from Agios Pharmaceuticals (AGIO).

Most Recent 13F
Q2 2026
Location
San Francisco, CA
CIK
0001056807
Portfolio Value
$2.5B (Q1 2025)
SEC Filing
0000921895-25-001528 ↗ filed May 15, 2025

Holdings Value

0$1.0B$2.0B$3.0B$4.0B Q1 2024: $3.6B Q1 2024 Q2 2024: $3.6B Q2 2024 Q3 2024: $3.4B Q3 2024 Q4 2024: $3.0B Q4 2024 Q1 2025: $2.5B $2.5B Q1 2025 Q2 2025: $2.8B Q2 2025 Q3 2025: $2.5B Q3 2025 Q4 2025: $3.0B Q4 2025 Q1 2026: $3.1B Q1 2026 Q2 2026: $3.9B Q2 2026

Holdings 51 stocks · $2.5B

MLTX Moonlake Immunotherapeutics 31.45% 19,751,284 $771.7M No change
AXSM Axsome Therapeutics Inc. 8.03% 1,690,221 $197.1M Add +21.8%
RVMD Revolution Medicines Inc. 7.18% 4,982,384 $176.2M Add +19.2%
KYMR Kymera Therapeutics Inc. 5.76% 5,161,801 $141.3M No change
MIRM Mirum Pharmaceuticals Inc. 5.13% 2,796,513 $126.0M No change
PTGX Protagonist Therapeutics Inc. 5.08% 2,575,015 $124.5M Add +35.5%
GHRS GH Research PLC 3.97% 8,827,712 $97.4M Reduce -15.1%
XOMA Xoma Royalty Corporation 2.42% 2,983,026 $59.5M Reduce -17.9%
IONS Ionis Pharmaceuticals Inc. 2.35% 1,913,385 $57.7M New
ZYME Zymeworks Inc. 2.09% 4,308,935 $51.3M No change
KURA Kura Oncology Inc. 2.09% 7,754,129 $51.2M Add +202.0%
CGEM Cullinan Therapeutics Inc. 1.77% 5,750,683 $43.5M No change
ACIU Ac Immune SA 1.51% 19,822,436 $37.1M Add +1.5%
TYRA Tyra Biosciences Inc. 1.50% 3,944,194 $36.7M No change
LKFT Lakefront Biotherapeutic-ADR filed as GALAPAGOS NV 1.49% 1,454,422 $36.5M Reduce -7.3%
CELC Celcuity Inc. 1.43% 3,466,000 $35.0M No change
VERV Verve Therapeutics Inc. 1.29% 6,904,050 $31.6M No change
GPCR Structure Therapeutics Inc. 1.25% 1,771,417 $30.7M No change
XNCR Xencor Inc. 1.19% 2,740,141 $29.2M Add +19.7%
GLUE Monte Rosa Therapeutics Inc. 1.07% 5,660,132 $26.3M Add +104.8%
SEPN Septerna Inc. 1.04% 4,396,124 $25.5M Add +79.3%
ELDN Eledon Pharmaceuticals Inc. 0.87% 6,293,282 $21.3M No change
CDTX Cidara Therapeutics Inc. 0.81% 924,642 $19.9M Reduce -15.4%
OLMA Olema Pharmaceuticals Inc. 0.81% 5,295,893 $19.9M Reduce -7.3%
PVLA Palvella Therapeutics Inc. 0.79% 696,555 $19.5M No change
FHTX Foghorn Therapeutics Inc. 0.79% 5,302,000 $19.4M No change
ITOS Iteos Therapeutics Inc. 0.75% 3,075,000 $18.4M Add +32.3%
FDMT 4D Molecular Therapeutics Inc. 0.60% 4,561,289 $14.7M Add +70.8%
EPIX Essa Pharma Inc. 0.56% 8,748,629 $13.8M No change
ANNX Annexon Inc. 0.55% 7,000,000 $13.5M No change
VSTM Verastem Inc. 0.52% 2,100,468 $12.7M No change
RAPT THERAPEUTICS INC 0.46% 9,237,556 $11.3M No change
RPTX Repare Therapeutics Inc. 0.42% 10,333,600 $10.2M No change
IMUX Immunic Inc. 0.40% 8,902,972 $9.7M No change
AVTX Avalo Therapeutics Inc. 0.34% 1,036,679 $8.3M No change
THRD Third Harmonic Bio Inc. 0.34% 2,372,933 $8.2M No change
VIGL Vigil Neuroscience Inc. 0.29% 4,013,633 $7.1M Add +121.3%
TCRX Tscan Therapeutics Inc. 0.28% 4,889,474 $6.7M Add +63.6%
MOLN Molecular Partners AG -ADR 0.22% 1,353,968 $5.5M No change
IKENA ONCOLOGY INC 0.21% 4,006,564 $5.1M No change
FBRX Forte Biosciences Inc. 0.19% 594,282 $4.6M No change
ALLK Allakos LLC 0.15% 16,552,417 $3.8M No change
CTMX Cytomx Therapeutics Inc. 0.14% 5,228,461 $3.3M No change
TENX Tenax Therapeutics Inc. 0.09% 339,549 $2.2M No change
IVA Inventiva SA - ADR 0.08% 686,040 $2.1M No change
GLYCOMIMETICS INC 0.08% 9,544,262 $2.0M No change
SABS Sab Biotherapeutics Inc. 0.05% 917,826 $1.2M No change
NAMS Newamsterdam Pharma Co. NV 0.05% 59,065 $1.2M New
OVID Ovid Therapeutics Inc. 0.05% 3,853,818 $1.2M No change
ENGENE HOLDINGS INC 0.02% 945,402 $605K No change
NLS PHARMACEUTICS LTD 0.01% 143,676 $221K No change

Portfolio Sells Q4 2024 → Q1 2025

AGIO Agios Pharmaceuticals Inc. Sold out 0.00% −1.20
ETNB 89BIO Inc. Sold out 0.00% −1.15
XOMA Xoma Royalty Corporation Reduce -17.9% 2.42% −0.81
ENGN Engene Holdings Inc. Sold out 0.00% −0.47
OLMA Olema Pharmaceuticals Inc. Reduce -7.3% 0.81% −0.32
CDTX Cidara Therapeutics Inc. Reduce -15.4% 0.81% −0.18
ELEV Elevation Oncology Inc. Sold out 0.00% −0.06
LKFT Lakefront Biotherapeutic-ADR Reduce -7.3% 1.49% +0.03
GHRS GH Research PLC Reduce -15.1% 3.97% +1.50

Portfolio Buys Q4 2024 → Q1 2025

AXSM Axsome Therapeutics Inc. Add +21.8% 8.03% +4.05
PTGX Protagonist Therapeutics Inc. Add +35.5% 5.08% +2.59
IONS Ionis Pharmaceuticals Inc. New 2.35% +2.35
KURA Kura Oncology Inc. Add +202.0% 2.09% +1.33
RVMD Revolution Medicines Inc. Add +19.2% 7.18% +0.98
GLUE Monte Rosa Therapeutics Inc. Add +104.8% 1.07% +0.42
VIGL Vigil Neuroscience Inc. Add +121.3% 0.29% +0.19
ITOS Iteos Therapeutics Inc. Add +32.3% 0.75% +0.14
FDMT 4D Molecular Therapeutics Inc. Add +70.8% 0.60% +0.10
NAMS Newamsterdam Pharma Co. NV New 0.05% +0.05
TCRX Tscan Therapeutics Inc. Add +63.6% 0.28% −0.03
ACIU Ac Immune SA Add +1.5% 1.51% −0.28
XNCR Xencor Inc. Add +19.7% 1.19% −0.59
SEPN Septerna Inc. Add +79.3% 1.04% −0.87

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 43$3.9BRVMD, KYMR, XOMA, MLTX, GHRS
Q1 2026 41$3.1BKYMR, MLTX, RVMD, NKTR, GPCR
Q4 2025 41$3.0BKYMR, RVMD, MLTX, GPCR, OLMA
Q3 2025 46$2.5BKYMR, RVMD, PTGX, MLTX, CDTX
Q2 2025 44$2.8BMLTX, KYMR, RVMD, PTGX, AXSM
Q1 2025 51$2.5BMLTX, AXSM, RVMD, KYMR, MIRM
Q4 2024 53$3.0BMLTX, KYMR, RVMD, AXSM, MIRM
Q3 2024 55$3.4BMLTX, KYMR, RVMD, MIRM, TYRA
Q2 2024 60$3.6BMLTX, RVMD, KYMR, IONS, MIRM
Q1 2024 62$3.6BMLTX, KYMR, RVMD, FDMT, GHRS